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Expression of TDP-43 C-terminal fragments in vitro
recapitulates pathological features of TDP-43 proteinopathies
Abstract
The disease protein in frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
and amyotrophic lateral sclerosis (ALS) was identified recently as the TDP-43 (TAR DNA-binding
protein 43), thereby providing a molecular link between these two disorders. In FTLD-U and ALS,
TDP-43 is redistributed from its normal nuclear localization to form cytoplasmic insoluble aggregates.
Moreover, pathological TDP-43 is abnormally ubiquitinated, hyperphosphorylated, and N-terminally
cleaved to generate C-terminal fragments (CTFs). However, the specific cleavage site(s) and the
biochemical properties as well as the functional consequences of pathological TDP-43 CTFs remained
unknown. Here we have identified the specific cleavage site, Arg(208), of a pathological TDP-43 CTF
purified from FTLD-U brains and show that the expression of this and other TDP-43 CTFs in cultured
cells recapitulates key features of TDP-43 proteinopathy. These include the formation of cytoplasmic
aggregates that are ubiquitinated and abnormally phosphorylated at sites found in FTLD-U and ALS
brain and spinal cord samples. Furthermore, we observed splicing abnormalities in a cell culture system
expressing TDP-43 CTFs, and this is significant because the regulation of exon splicing is a known
function of TDP-43. Thus, our results show that TDP-43 CTF expression recapitulates key biochemical
features of pathological TDP-43 and support the hypothesis that the generation of TDP-43 CTFs is an
important step in the pathogenesis of FTLD-U and ALS.
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 The disease protein in frontotemporal 
lobar degeneration with ubiquitin-positive 
inclusions (FTLD-U) and amyotrophic lateral 
sclerosis (ALS) was identified recently as the 
TAR DNA-binding protein (TDP-43) thereby 
providing a molecular link between these two 
disorders. In FTLD-U and ALS, TDP-43 is 
redistributed from its normal nuclear 
localization to form cytoplasmic insoluble 
aggregates. Moreover, pathological TDP-43 is 
abnormally ubiquitinated, 
hyperphosphorylated and N-terminally cleaved 
to generate C-terminal fragments (CTFs). 
However, the specific cleavage site(s) and the 
biochemical properties as well as the functional 
consequences of pathological TDP-43 CTFs 
remained unknown. Here we have identified 
the specific cleavage site, Arg 208, of a 
pathological TDP-43 CTF purified from FTLD-
U brains and show that the expression of this 
and other TDP-43 CTFs in cultured cells 
recapitulates key features of TDP-43 
proteinopathy. These include the formation of 
cytoplasmic aggregates that are ubiquitinated 
and abnormally phosphorylated at sites found 
in FTLD-U and ALS brain and spinal cord 
samples. Furthermore, we observed splicing 
abnormalities in a cell culture system 
expressing TDP-43 CTFs, and this is significant 
because the regulation of exon splicing is a 
known function of TDP-43. Thus, our results 
show that TDP-43 CTF expression 
recapitulates key biochemical features of 
pathological TDP-43, and support the 
hypothesis that the generation of TDP-43 CTFs 
is an important step in the pathogenesis of 
FTLD-U and ALS.  
 
TAR DNA-binding protein 43 (TDP-43) 
is the major disease protein of sporadic and 
familial frontotemporal lobar degeneration 
(FTLD) with ubiquitin-positive, tau-negative 
inclusions (FTLD-U) with or without motor 
neuron disease (MND) as well as sporadic and the 
majority of familial amyotrophic lateral sclerosis 
(ALS) cases (1,2). Human TDP-43 is encoded by 
the TARDBP gene on Chromosome 1. It is a 414 
amino acid nuclear protein with two highly 
conserved RNA recognition motifs (RRM1 and 
RRM2) and a C-terminal tail with a typical 
glycine-rich region that mediates protein-protein 
interactions, including interactions with other 
heterogeneous ribonucleoprotein (hnRNP) family 
members such as hnRNP A1, A2/B1 and A3 (3). 
Thus, TDP-43 is a ubiquitously expressed 
RNA/DNA binding protein that also interacts with 
other nuclear proteins such as splicing factors. As 
such, TDP-43 is implicated in repression of gene 
transcription, regulation of exon splicing and the 
functions of nuclear bodies (4-9).  
Pathological TDP-43 accumulates as 
insoluble aggregates in central nervous system 
neurons and glia of patients with FTLD-U and 
ALS (1). Moreover, FTLD-U patients can develop 
ALS and ALS patients often suffer from a 
dementia consistent with FTLD-U (10). We 
therefore proposed that these diseases are part of a 
clinicopathological spectrum of the same 
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neurodegenerative process collectively referred to 
as TDP-43 proteinopathy (1,2). TDP-43 inclusions 
are present as cytoplasmic, neuritic or nuclear 
inclusions and affected neurons show a dramatic 
depletion of normal nuclear TDP-43 (1,11,12). To 
mimic this nuclear clearance and to model the 
sequestration of endogenous TDP-43 into 
cytoplasmic aggregates, we overexpressed TDP-
43 with mutated nuclear localization signals 
(ΔNLS-TDP-43) in cultured cells that showed a 
reduction in endogenous nuclear TDP-43 and 
accumulations of insoluble cytoplasmic aggregates 
(13). Moreover, overexpression of TDP-43 with a 
mutated nuclear export signal (ΔNES-TDP-43) 
resulted in the formation of insoluble nuclear 
TDP-43 aggregates (13).  
Pathological TDP-43 is 
hyperphosphorylated, ubiquitinated and 
abnormally cleaved so that C-terminal fragments 
(CTFs) of TDP-43 accumulate in cells of affected 
CNS areas (1). Indeed, we recently showed that 
insoluble TDP-43 CTFs are selectively enriched in 
affected cortical regions compared with spinal 
cord of both FTLD-U and ALS cases (14). These 
observations suggest that TDP-43 is differentially 
processed in brain versus spinal cord, and that 
TDP-43 CTFs might seed inclusion formation and 
aggregation in cortical neurons. Since CTFs 
contain the TDP-43 glycine-rich region, the 
accumulation of CTF-rich aggregates may result in 
abnormal interactions with proteins involved in the 
splicing machinery of affected cells. However, 
little is known about how pathological TDP-43 is 
cleaved to generate TDP-43 CTFs or the 
biochemical properties of disease-related TDP-43 
CTFs.  
Here we address these questions by 
identifying the cleavage site of an endogenous 
TDP-43 CTF purified from FTLD-U brains. We 
also model the aggregation of this and several 
other TDP-43 CTFs in the cytoplasm of cultured 
cells and show that expression of TDP-43 CTFs is 
sufficient to generate cytoplasmic aggregates. 
Moreover, these insoluble CTFs are ubiquitinated 
and abnormally phosphorylated at sites similar to 
those in human FTLD-U and ALS CNS samples. 
Finally, we demonstrate that cells expressing 
TDP-43 CTFs display abnormal splicing of the 
cystic fibrosis transmembrane conductance 
regulator (CFTR) which is relevant to TDP-43 
function since alternative splicing of this gene is 
known to be regulated by TDP-43 (6). Our results 
recapitulate unique features of pathological TDP-
43 that are hallmarks of FTLD-U and ALS and 
implicate the generation of TDP-43 CTFs as a key 
event in the pathogenesis of TDP-43 
proteinopathies. 
 
EXPERIMENTAL PROCEDURES 
 
Constructs. N-terminal truncations (see below) 
were generated by PCR of human TDP-43 using 
the following primers: 177-TDP-43, 
5’GGATCCATGC 
TTCCTAATTCTAAGCAAAGCC-3’; 187-TDP-
43, 5’-GGATCCATGC 
CTTTGAGAAGCAGAAAAGTGT-3’; 197-TDP-
43, 5’-GGATCCA 
TGCGCTGTACAGAGGACATGACTG-3’; 208-
TDP-43, 5’-GGATCCC 
GGGGTTCTTCTCTCAGTACGGGGAT-3’, and 
5’-TCTAGAG 
CTACATTCCCCAGCCAGAAGACTTAGA-3’. 
The addition of a myc epitope tag to the 5’-end of 
the TDP-43 N-terminal truncations was achieved 
by PCR, using the following primers; 5- Myc-177-
TDP-43, 5’-
GGATCCATGGAACAAAAACTCATCTCGGA
A 
GAGGATCTGCTTCCT 
AATTCTAAGCAAAGCC-3’; Myc-187-TDP-43, 
5’-
GGATCCATGGAACAAAAACTCATCTCGGA
AGAGGATCTGCCTTTGAGAAGCAGAAAAG
TGT-3’; Myc-197-TDP-43, 5’-
GGATCCATGGAACAAAAACT 
CATCTCGGAAGAGGATCTGCGCTGTACAG
AGGACATGACTG-3’, Myc- 
208-TDP-43, 5’-
GGATCCATGGAACAAAAACTCATCTCGGA 
AGAGGATCTGCGGGAGTTCTTCTCTCAGTA
CGGGGAT-3, and  5’-TCTAGAG 
CTACATTCCCCAGCCAGAAGACTTAGA-3’. 
All PCR products were cloned into the pGEM-T 
vector (Promega, Madison, WI). Following 
sequence analysis the PCR products were 
subcloned into pcDNA 5/To plasmid (Invitrogen) 
using restriction sites BamHI and XbaI. A diagram 
of each TDP-43 CTF is shown in Fig. 1B. Myc-
WT-TDP-43, Myc-ΔNLS-TDP-43 and Myc-
ΔNES-TDP-43 were previously described (13). 
Human TDP-43 shRNA (targeted to the 3’ UTR 
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region) was obtained from OriGene (Rockville, 
MD, Cat. No. TR308946). pcDNA 3.1 alpha-
synuclein was previously described (15). 
Antibodies. Commercial antibodies used in this 
study were: rabbit anti-TDP-43 polyclonal (pAb) 
raised to aa 1-260 (Protein Tech Group, Chicago, 
IL), a human specific mouse monoclonal (mAb) 
raised to the same TDP-43 sequence (2E2-D3) 
(Abnova, Taipei, Taiwan), anti-myc mAb (9E10, 
Santa Cruz Biotechnology, Santa Cruz, CA), anti-
HA (12CA5 mouse mAb, Roche Applied 
Bioscience, Indianapolis, IN)  and anti-α-GAPDH 
(6C5 mouse mAb, Advanced ImmunoChemical 
Inc, Long Beach, CA). A rabbit anti-TDP-43 pAb 
raised to aa 394-414 (C-t TDP-43 pAb) was 
described previously (14). A rat phospho-specific 
mAb that recognizes TDP-43 phosphorylated at 
Ser409/Ser410 (p409/410 TDP-43) was developed 
and characterized elsewhere (16). 
Immunoprecipitation (IP) and N-terminal 
Cleavage Site Analysis.  Sarkosyl-insoluble urea 
soluble extracts from FTLD-U brains with 
abundant TDP-43 CTFs were used for IP. Because 
N-terminal cleaved TDP-43 fragments migrate 
similarly as IgG light chains, anti-TDP-43 specific 
mAbs were cross-linked to protein A/G agarose 
(Santa Cruz Biotech., Inc., Santa Cruz, CA) with 
the homobifunctional imidoester cross-linker 
dimethyl pimelimidate for IP use. Dialyzed urea 
fractions in RIPA buffer (0.1% sodium dodecyl 
sulfate [SDS], 1% NP40, 0.5% sodium 
dexoycholate, 5 mM EDTA, 150 mM NaCl, 50 
mM Tris-HCl, pH 8.0) or diluted SDS fractions 
from CNS were pre-cleared with protein A/G 
agarose and subjected to IP with antibody-protein 
A/G-agarose beads. Bound proteins and fragments 
were then eluted from the beads with SDS sample 
buffer without DTT (10 mM Tris-HCl, pH 6.8, 1 
mM EDTA, 1% SDS, 10% sucrose) at 80°C to 
minimize the dissociation of IgG light chain from 
the bead complex. Eluted proteins were reduced 
with DTT at elevated temperature before 
resolution by 12% Bis-Tris NuPage® (Invitrogen, 
Carlsbad, CA) SDS-PAGE using MOPS buffer 
system and transferred to sequence grade PVDF 
membranes (Bio Rad Laboratories, Hercules, CA). 
Typically, two gels were run, one for 
immunoblotting and the other for N-terminal 
sequencing. For N-terminal sequencing, the 
membrane was stained with 0.1% Amido Black, 
and protein bands that correspond to the TDP-43 
immuno-positive bands (~20-25 kDa) on the 
companion immunoblots were excised. Cleavage 
sites of TDP-43 fragments were determined by N-
terminal automated Edman sequencing on an 
Applied Biosystems 494 Protein Sequencer at the 
Wistar Institute Proteomics Facility. At minimum, 
8 cycles of sequencing are conducted for amino 
acid sequence.  
Cell Culture and Transfection.  QBI-293, Neuro2a 
and COS-7 cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin (P/S) and 1% L-glutamate. Cells 
were transfected using the Lipofectamine 2000 
reagent (Invitrogen) according to the 
manufacturer’s instructions. In some experiments, 
transfected cells were treated with 10 μM MG132 
(Sigma-Aldrich, St. Louis, MO) for 16 hrs. 
Immunofluorescence Studies.  Cells were fixed in 
4% paraformaldehyde in phosphate-buffered 
saline (PBS), permeabilized with 0.2% Triton X-
100 (Sigma) in PBS for 10 min, blocked with 5% 
powdered-milk in PBS for 2 hrs and incubated 
overnight with primary antibody at 4ºC. Primary 
antibodies were visualized with secondary 
antibodies conjugated with Alexa Fluor 488 and 
Alexa Fluor 594 (Vector Laboratories, Burlingame, 
CA) and nuclei were detected using DAPI. All 
cells were analyzed using a Nikon TE-2000-E 
(Nikon, Tokyo, Japan) and images were captured 
using a CoolSnap-HQ camera (Photometrics, 
Tuscon, AZ). All micrographs show images 
representative of the total cell population. For 
quantification of aggregates, several random fields 
per sample were analyzed and the percentage of 
transfected cells that displayed TDP-43 positive 
accumulations was calculated.  
Solubility and Biochemical Analysis.  To examine 
the solubility profile of TDP-43, sequential 
extractions were performed. Cells were washed 
twice with PBS, lysed in cold RIPA buffer 
containing 1 mM PMSF, a cocktail of protease 
inhibitors (PI) (1 mg/ml Pepstatin, Leuptin, TPCK, 
TLCK, trypsin inhibitor; Sigma) and a cocktail of 
phosphatase inhibitors (PPI) (2 mM imidazole, 1 
mM NaF, 1 mM sodium orthovanadate, Sigma). 
Cell lysates were sonicated and then cleared by 
centrifugation at 100,000 x g for 30 min at 4ºC to 
generate the RIPA soluble samples. To prevent 
carry-overs, the resulting pellets were washed with 
RIPA buffer (i.e. re-sonicated and re-centrifuged). 
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Only the supernatants from the first centrifugation 
were analyzed. RIPA insoluble pellets were then 
extracted with urea buffer (7M urea, 2M thiourea, 
4% 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS), 30mM Tris, pH 8.5), 
sonicated and centrifuged at 70,000 x g for 30 min 
at 22ºC. Protease and phosphatase inhibitors were 
added to all buffers prior to use (1 mM PMSF and 
a cocktail of PI and PPI). Protein concentration 
was determined by bicinchoninic acid method 
(Pierce, Rockford, IL) and proteins were resolved 
by 10% or 15% SDS-PAGE and transferred to 
nitrocellulose membranes. Following transfer, 
nitrocellulose membranes were blocked in 5% 
powdered milk and incubated in the primary 
antibody overnight at 4ºC. Primary antibodies 
were detected with horseradish peroxidase (HRP)-
conjugated secondary antibodies (Jackson 
ImmunoResearch, Wegate, PA) and blots were 
developed with Renaissance Enhanced Luminal 
Reagents (NEN Life Science Products, Boston, 
MA). Digital images were acquired using a Fuji 
Film Intelligent Darkbox II (Fuji Systems, 
Stamford, CT). For quantification of TDP-43 
CTFs insolubility, densitometric analysis of RIPA-
soluble and insoluble fractions of at least 3 
different experiments was performed using Image 
Quant 5.0 software (Molecular Dynamics Inc, 
Sunnyvale, CA). Where indicated, cell lysates or 
postmortem brain tissue from FTLD-U cases 
sequentially extracted as previously described (1) 
were dephosphorylated by dialysis (20 mmol/L 
Tris and 0.2 mmol/L EDTA, pH 8.0) and treated 
with Escherichia coli alkaline phosphatase 
(Sigma) for 2 hr at 56 ºC. 
Splicing analysis. TDP-43 functional activity was 
assayed through evaluation of CFTR splicing. 
First, various TDP-43 constructs were transiently 
transfected into QBI-293 cells using 
Lipofectamine 2000 reagent (Invitrogen) 
following standard manufacturer protocols. Forty-
eight hr later, a hybrid minigene construct (a 
generous gift from Dr. F. Baralle, ICGEB, Trieste, 
Italy) designed to evaluate CFTR exon 9 splicing 
was transiently transfected into the same cells 
(6,17). Fig. S3B depicts the structure of the 
minigene construct, which consists of CFTR exon 
9 with portions of the CFTR flanking introns 
inserted between exons from a hybrid fibronectin-
alpha-globin gene (18). The relative exclusion of 
exon 9 in the presence of various TDP-43 
constructs was then evaluated by primer extension 
from the flanking exons of exon 9. Total RNA was 
prepared from cells 72 hours after transfection of 
TDP-43 constructs and 24 hours after transfection 
of the TG(13)T(5) CFTR minigene reporter 
construct, and RT-PCR was performed using 3 μg 
of total RNA and 2 μm of the resulting cDNA as 
described previously (17). The primers used were: 
Bra2 
TAGGATCCGGTCACCAGGAAGTTGGTTAA
ATCA; a2-3 
CAACTTCAAGCTCCTAAGCCACTGC. PCR 
conditions were as follows: 95º for 10 min (hot 
start), followed by 30 cycles of denaturing at 95º 
for 30 sec, annealing at 57º for 30 sec, and 
elongation at 72º for 60 sec. PCR products were 
visualized on a 1.5% agarose gel; relative amounts 
of different splice products were quantified and 
visualized using the Agilent 2100 Bioanalyzer on 
a DNA 1000 chip. Experiments were performed in 
duplicate and repeated at least three times.  
 
RESULTS 
 
N-terminally Cleaved Sites of TDP-43 CTFs. 
Previously, we have shown that cortical TDP-43 
inclusions in FTLD-U and ALS brains are 
composed predominantly of CTFs (14). To better 
understand the biological significance of the CTFs, 
we determined their cleavage sites by N-terminal 
sequencing. Cortical urea extracts of FTLD-U 
brains containing high levels of CTFs were 
immunoprecipitated (IP) with anti-TDP-43 mAb 
and the resultant proteins were resolved on SDS-
PAGE gels and immunoblotted with a polylconal 
antibody (pAb) raised to the extreme C-terminus 
(C-t) of TDP-43. Two protein bands with apparent 
Mr of ~24 kD and ~22 kD were recognized by the 
anti-C-t TDP-43 pAb (Fig. 1A). The same bands 
were identified on Amido Black-stained duplicate 
PVDF blots and were excised for N-terminal 
sequencing (arrows in Fig. 1A). Results from the 
~22 kD band gave a primary sequence beginning 
at Arg 208 in TDP-43 (Fig 1A, arrow with 
asterisk), but no sequence was obtained from the 
~24 kD band. Similar results were obtained from 
four separate experiments using two different 
FTLD-U cases. The identification of the N-
terminus of a CTF together with our previous 
LC/MSMS studies on TDP-43 CTFs showing the 
presence of residues at the extreme C-terminus (1), 
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allow us to conclude that we have identified a 
pathological TDP-43 fragment spanning amino 
acid residues 208-414 (designated as 208 TDP-43).  
 To study the biochemical properties of 
TDP-43 CTFs and to determine if the expression 
of these fragments recapitulated pathological 
features of authentic CTFs isolated from FTLD-U 
and ALS brains, we developed a series of vectors 
for expression in cultured cells. Plasmids 
containing the 208 TDP-43 CTF as well as slightly 
longer CTFs containing residues 177-414, 187-414 
or 197-414 of TDP-43 (designated as 177 TDP-43, 
187 TDP-43 and 197 TDP-43 respectively) were 
generated (Fig. 1B). Each TDP-43 CTF cDNA 
was expressed in QBI-293 cells, a human 
embryonic kidney cell line, as well as N2a, a 
mouse neuroblastoma cell line, and the 
electrophoretic mobility of the fragments migrated 
between 20-25 kD (Fig. 1C).  
 
TDP-43 CTFs Expressed in Cultured Cells are 
Insoluble and Hyperphosphorylated. Previous 
studies have shown that TDP-43 CTFs isolated 
from FTLD-U and ALS brains are insoluble and 
hyperphosphorylated (Neumann et al, 2006). To 
determine if these pathological properties can be 
recapitulated in cultured cells, we expressed all 4 
TDP-43 CTFs constructs (i.e. 177 TDP-43, 187 
TDP-43, 197 TDP-43 and 208 TDP-43) in N2a 
(Fig. 2) and QBI-293 [Supporting Information 
(SI) Fig. S1] cells. Sequential extraction of cells 
overexpressing each of the 4 CTFs with RIPA and 
urea buffers showed a progressive increase in the 
degree of RIPA insolubility going from the largest 
to the smallest CTF with 177 TDP-43 CTFs being 
the most soluble and 197 and 208 TDP-43 CTFs 
being the most insoluble (Fig. 2A, 2B and S1A). 
Quantitative immunoblotting showed that almost 
100% of the two smaller TDP-43 CTFs are 
insoluble in RIPA and can only be extracted by 
urea (Fig. 2B). However, expression of TDP-43 
CTFs tagged with the myc epitope in QBI-293 
cells (Fig. S2) increased their solubility when 
compared with their untagged counterparts 
(compare Figs. S1 and S2). 
We also detected multiple immunobands 
(particularly those recovered in the urea fractions) 
upon expression of TDP-43 CTFs in cultured cells 
(Figs. 2A and S1A). Since pathological TDP-43 
CTFs recovered from FTLD-U and ALS brains are 
hyperphosphorylated at multiple sites including 
hyperphosphorylation at Ser409 and Ser410 
(p409/410), we asked if the CTFs expressed in 
transfected cells are also hyperphosphorylated (19). 
Using a rat mAb specific for p409/410 (16), we 
found that all 4 TDP-43 CTFs displayed robust 
phospho-specific signals and that labeled phospho-
immunobands showed slower apparent 
electrophoretic mobility than the main protein 
band recognized by the anti-C-t TDP-43 pAb 
(Figs. 2A and S1A, red asterisks highlight the 
same immunobands detected by C-t TDP-43 and 
p409/410 antibodies and the black asterisk identify 
the main protein band recognized only by the anti-
C-t TDP-43 pAb). Significantly, although the 
electrophoretic mobility of non-phosphorylated 
208 TDP-43 CTFs was close to 20 kD, the 
phosphorylated counterpart migrated at ~ 22 kD. 
Moreover, phosphorylated TDP-43 CTFs were 
detected only in the urea fraction, and 
phosphorylation at Ser409 and Ser410 was not 
seen in endogenous TDP-43 recovered from RIPA 
extractions (Figs. 2A and S1A).  Thus, like 
pathological TDP-43 CTFs recovered from 
diseased brains, TDP-43 CTFs in our in vitro 
models are phosphorylated, and the 
phosphorylated TDP-43 CTFs are insoluble. 
To characterize the morphology of these 
phosphorylated, insoluble TDP-43 CTFs, we 
conducted double label immunofluorescence 
analysis of transfected cells using anti-C-t TDP-43 
pAb and the rat anti-p409/410 mAb. 
Phosphorylated Ser409/Ser410 was detected 
within C-t TDP-43-positive aggregates when each 
of the 4 TDP-43 CTFs was expressed (Figs. 2C 
and S1B). Phosphorylated endogenous nuclear 
TDP-43 was not seen in control or untransfected 
cells and foci of aggregated phosphorylated TDP-
43 CTFs were observed within diffuse cytoplasmic 
TDP-43 immunoreactivity when longer, more 
soluble CTFs (e.g. 177 TDP-43) were expressed 
(Fig. 2C and S1B). Occasionally, we observed 
CTFs in the nucleus and we attribute this to the 
overexpression and small size of the CTFs. Finally, 
we also observed a direct correlation between the 
solubility of the TDP-43 CTFs and aggregate 
formation such that the more insoluble CTFs, i.e. 
208 TDP-43, consistently showed increased 
percentage of inclusion-bearing cells with larger 
aggregates (Fig. 2B, 2D). Similar results were 
obtained using a third cell line – COS-7 cells (data 
not shown).  
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To determine if the size of our 
phosphorylated TDP-43 CTFs expressed in 
cultured cells correspond to endogenous CTFs 
from FTLD-U brains, we compared the 
electrophoretic mobility of TDP-43 fragments 
expressed in N2a cells and showed that they 
resembled the pathological FTLD-U fragments 
(Fig. 3A). Indeed, since the phosphorylated 208 
TDP-43 fragment expressed in N2a cells co-
migrated with an immunoband at ~ 22 kD of TDP-
43 CTFs from FTLD-U brains, we suggest that the 
origin of our N-terminal sequenced fragment 
beginning with Arg 208 came from a 
phosphorylated FTLD-U CTF (Fig. 3A). 
Dephosphorylated TDP-43 CTFs from N2a cells 
also co-migrated with FTLD-U CTFs (Fig. 3B). 
Therefore, although the exact cleavage sites of the 
larger TDP-43 CTFs from FTLD-U brains remain 
to be determined, the close resemblance of the 
electrophoretic migration of these fragments to 
those expressed in N2a cells suggest that the 
biochemical properties of the expressed fragments 
we observed here likely reflect that of pathological 
TDP-43 CTFs in disease brains. 
To determine if full length TDP-43 
expressed in the cytoplasm is also phosphorylated, 
we transfected mutant TDP-43 with defective 
nuclear localization signals (ΔNLS-TDP-43) that 
we characterized in a previous study (13) and 
found robust phosphorylation at Ser409/410 of 
ΔNLS-TDP-43 in the insoluble fraction (Fig. 4A, 
4B). Interestingly, phosphorylation of Ser409/410 
was not detected in RIPA soluble ΔNLS-TDP-43 
or overexpressed WT-TDP-43 in both the RIPA 
and urea fractions. Similar results were obtained 
using N2a cells (data not shown). Thus, 
phosphorylation of both full length and CTFs of 
TDP-43 at Ser409/410 is detected in the insoluble 
cytoplasmic aggregates. Taken together, these 
observations suggest a correlation between 
phosphorylation and insolubility, regardless 
whether TDP-43 accumulates as the full length 
protein or as CTFs in the cytoplasm.  
 
TDP-43 CTF Aggregates are Ubiquitinated. We 
recently showed that ubiquitin-positive TDP-43 
inclusions in FTLD-U and ALS brains are 
enriched in TDP-43 CTFs (14). Therefore, we 
investigated whether aggregated TDP-43 CTFs in 
transfected cells were also ubiquitinated. 
Immunofluorescence analysis of transfected N2a 
or QBI-293 cells displayed strong colocalization 
of aggregated TDP-43 with ubiquitin; this was not 
seen in non-transfected neighboring cells or 
vector-only transfected cells (Fig. 5A and data not 
shown). To directly demonstrate that TDP-43 
CTFs are ubiquitinated, 187 TDP-43 was 
cotransfected with HA-tagged ubiquitin and 
incubated with or without MG132, a proteasome 
inhibitor. Immunoprecipitation of the cell lysates 
with TDP-43 antibodies followed by 
immunoblotting with anti-HA antibody (12CA5 
mAb) revealed a high MW smear of ubiquitinated 
TDP-43 species, enhanced in the presence of 187 
TDP-43 expression (Fig. 5B). Control 
immunoprecipitation reactions carried out using an 
unrelated antibody (anti-tau T46 mAb) showed 
little or no high MW smear, irrespective of TDP-
43 CTF expression (data not shown). MG132 
treatment after transfection greatly increased the 
abundance of ubiquitinated TDP-43 concomitant 
with TDP-43 CTF expression (Fig. 5B). Lack of 
TDP-43-positive high MW smear in the TDP-43 
immunoblot is likely due to relatively low levels 
of ubiquitinated CTFs and as such below the 
sensitivity for detection with this antibody. These 
results are consistent with the notion that 
exogenous expression of TDP-43 CTFs leading to 
the formation of cytoplasmic aggregates also 
results in increased ubiquitination. 
 
Accumulation of TDP-43 CTFs Compromises RNA 
Splicing of CFTR. One of the biological functions 
of TDP-43 described previously is the regulation 
of alternative splicing. In particular, exon skipping 
mediated through interactions of TDP-43 with 
GU-repeats in CFTR and ApoAII pre-mRNA 
transcripts has been reported (6,7), while the 
enhancement of exon inclusion for the SMN2 gene 
has been reported upon overexpression of TDP-43 
(8). To determine whether expression of TDP-43 
CTFs had any impact on this known biological 
function of TDP-43, we analyzed splicing 
efficiency using a previously described minigene 
reporter system (Fig. S3A, S3B) (6). In agreement 
with previous observations, control experiments in 
cells transfected with WT-TDP-43 or a TDP-43 
shRNA demonstrate that TDP-43 overexpression 
or depletion (>90%) led to a decrease or an 
increase in CFTR exon 9 inclusion, respectively 
(Fig. 6A, 6B and S3C). Surprisingly, expression 
of all four TDP-43 CTFs tested resulted in a 
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decrease in exon-skipping activity relative to 
control-transfected cells, suggesting a loss-of-
function consequence of CTF generation (Fig. 6A, 
6B and S3C). The expression of WT-TDP-43 
protein, the knockdown of endogenous TDP-43, 
and expression of all 4 TDP-43 CTFs were 
confirmed in the same samples employed for RNA 
isolation using immunoblot analysis of transfected 
QBI-293 cells (Fig. S3A and S3D). This effect 
was specific to the TDP-43 CTFs since parallel 
transfection of α-synuclein, a protein not known to 
affect RNA splicing, into the same cell line 
showed no impact on CFTR reporter splicing 
activity (data not shown).  It is noteworthy that 
while these TDP-43 CTFs do not possess the first 
RNA-recognition motif (RRM1) required for 
efficient RNA and DNA binding, they still encode 
the entire C-terminal region containing the 
glycine-rich domain that is critical for interactions 
of TDP-43 with proteins displaying known 
splicing inhibitory activity such as hnRNPs (3,20). 
Taken together, these results provide the first 
evidence of impaired splicing regulatory activity 
in the presence of abnormal TDP-43 species 
associated with FTLD-U and ALS pathology. 
 
DISCUSSION 
 
 Our study investigated the role of TDP-43 
CTFs in the pathogenesis of two 
neurodegenerative TDP-43 proteinopathies, i.e. 
FTLD-U and ALS. To that end, we recovered 
pathological TDP-43 CTFs from FTLD-U brains 
and provided the identity of one fragment 
encompassing amino acid residues 208-414. We 
further showed that expression of either the 208-
414 TDP-43 CTF or slightly longer CTFs in cell 
culture systems resulted in the formation of 
ubiquitinated and hyperphosphorylated CTF 
aggregates. Finally, we demonstrated that TDP-43 
CTF accumulation alters the splicing pattern of the 
TDP-43 mRNA target CFTR. These findings show 
that the generation of CTFs is sufficient to initiate 
a number of events – cytoplasmic localization, 
ubiquitination, phosphorylation and aggregation of 
TDP-43 CTFs– that mirror TDP-43 proteinopathy, 
and that these events have functional 
consequences on gene splicing. 
 Structurally, it is not surprising that the C-
terminal region of TDP-43 may be important in 
disease pathogenesis, as this region harbors 
several remarkable features. Although the general 
domain architecture of TDP-43 is similar to that of 
other RNA-binding proteins of the RRM family 
such as hnRNPs, in silico analysis of the extreme 
C-terminal portion of TDP-43 (PSIPRED Server 
(21)) indicates that this region displays little 
organized secondary structure. In this regard, 
although the full length protein contains typical 
motifs (i.e. RRMs and glycine-rich domains), 
CTFs of TDP-43 (such as those found in disease 
and modeled in this study) may be viewed as 
functionally different entities which share some 
commonalities with other proteins linked to 
neurodegeneration, such as alpha-synuclein. These 
comparatively disordered peptides are 
aggregation-prone if the right conditions or post-
translational modifications are present. 
Genetically, TDP-43’s C-terminal region 
is implicated in pathogenesis as well. The 
discovery of multiple ALS-associated TARDBP 
mutations that map almost exclusively to the C-
terminal domain constitutes an intriguing reminder 
of the potential link between abnormal TDP-43 
post-translational modification, localization or 
conformation, and the pathogenesis of TDP-43 
proteinopathies (22-25). Interestingly, several of 
these reported mutations may create novel 
phosphorylation sites through substitution to 
serine, which could provide the basis for abnormal 
properties of mutated TDP-43. Testing of such a 
hypothesis awaits the availability of more human 
neuropathological material from TARDBP 
mutation patients. 
 In the experiments described here, we 
found TDP-43 CTFs to be relatively insoluble and 
aggregation-prone similar to recent results in yeast 
(26). Specifically, the expression of a GFP-tagged 
TDP-43 construct encoding a CTF (188-414 TDP-
43, similar to a CTF used in this study) in yeast led 
to the formation of cytoplasmic aggregates as well 
as cellular toxicity. Yeast and mammalian cells 
appear to show some important differences in their 
handling of TDP-43, however. For example, N-
terminal fragments of TDP-43 used in the same 
yeast study remained in the nucleus and showed 
no apparent aggregation or effect on cell survival 
(26). In contrast, N-terminal fragments of TDP-43 
expressed in a mammalian cell culture system 
have been reported to mislocalize and form 
inclusions (27). Unlike in yeast cells, epitope-
tagged TDP-43 CTFs are more soluble than their 
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untagged counterparts when expressed in 
mammalian cells (Fig. S2B). Thus, the 
biochemical profile of TDP-43 truncations appears 
to be sensitive to the cellular system used for study. 
 Our data show that expression of 
predominantly cytoplasmic species of TDP-43 (i.e. 
CTFs or NLS mutants) results in phosphorylation 
by an endogenous mechanism at residues that are 
pathologically hyperphosphorylated in human 
TDP-43 proteinopathies such as FTLD-U and ALS. 
Moreover, immunoblot and immunocytochemistry 
data showed that this abnormal phosphorylation is 
seen only with insoluble aggregated TDP-43. 
These data are compatible with a model of 
pathogenesis whereby cytoplasmic species of 
TDP-43 generated by proteolysis and/or 
redistribution become hyperphosphorylated and 
ubiquitinated. Other less likely possibilities 
include that hyperphosphorylation decreases 
solubility and promote aggregation or that more 
insoluble species are preferential substrates for yet 
to be determined protein kinases. Overall, our 
CTFs results suggest that proteolytic cleavage of 
TDP-43 may constitute an important event for 
aggregate formation, occurring independently or 
upstream of hyperhosphorylation. 
 If cytoplasmically localized, abnormally 
hyperphosphorylated and insoluble/aggregated 
CTFs are bona fide features of disease, what are 
their downstream functional consequences? This 
question is difficult to answer because the 
functions of normal TDP-43 remain incompletely 
understood. One relatively well-characterized 
biological function of TDP-43, however, is in the 
regulation of alternative splicing –  specifically, 
the splicing of CFTR, Apo IIA, and SMN (6-8). 
Of these, the most thoroughly studied splicing 
function of TDP-43 to date has been CFTR exon 9 
skipping, which is mediated through (UG)m(U)n 
regulatory regions to which TDP-43 binds (6). In 
the present study, we showed that expression of 
TDP-43 CTFs alters CFTR splicing, arguing that 
the generation of pathological CTFs affects normal 
TDP-43 function. We postulate that this effect 
may result from altered interactions with members 
of the hnRNP family of splicing factors. In vitro 
studies have determined that several members of 
the hnRNP family (A1, A2/B1, A3 and C1/C2) 
interact with TDP-43 through its C-terminal region 
(3). Since hnRNP A/B proteins have known 
inhibitory splicing properties, the effect of TDP-43 
on exon skipping could be mediated via 
recruitment of an hnRNP-rich inhibitory complex 
through its C-terminal tail (3,28). Given that 
several of these interactors have been shown to 
shuttle between the cytoplasm and the nucleus 
(29), excess glycine-rich CTFs in the cytoplasm 
could alter the nucleocytoplasmic equilibrium of 
available hnRNP proteins, affecting not only TDP-
43-mediated targets but also many different 
splicing and mRNA export pathways involving 
hnRNPs. Dysregulation of gene expression could 
then cause downstream disease effects in TDP-43 
proteinopathies.  
 In this study, we investigated the 
hypothesis that TDP-43 CTFs are central to 
disease pathogenesis since they are seen in 
affected CNS regions from FTLD-U and ALS 
patients and absent in the CNS of normal 
individuals. By identifying Arg 208 as one of the 
cleavage sites of endogenous CTFs from FTLD-U 
brains and by demonstrating that this and other 
larger TDP-43 CTFs expressed in cultured cells 
co-migrate with pathological CTFs, we have 
generated TDP-43 CTF constructs to study the 
biochemical properties of the fragments. We 
showed that simply by expressing TDP-43 CTFs 
in a cell culture system, one can recapitulate key 
biochemical features of TDP-43 in disease – i.e. 
insolubility, aggregation, ubiquitination, and 
hyperphosphorylation. We also showed that 
expression of TDP-43 CTFs is sufficient to 
provoke a partial loss of one of the only known 
biological functions of TDP-43 – regulation of 
CFTR exon 9 splicing. These findings support the 
idea that generation of TDP-43 CTFs is an 
important event in FTLD-U and ALS pathogenesis. 
Thus, we believe that the cell culture model 
described here will be useful in identifying 
endogenous signaling cascades that lead to TDP-
43 phosphorylation, assessing the impact of 
splicing alteration on cellular metabolism, and 
elucidating mechanisms of aberrant protein-
protein interaction displayed by pathological TDP-
43 species. This information, in turn, will be vital 
in the development of targeted therapies for these 
neurodegenerative diseases. 
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FIGURE LEGENDS 
 
Figure 1. N-terminal Cleavage Site Identification and Generation of TDP-43 CTFs. (A) CTFs used 
for N-terminal cleavage site determination after immunoprecipation proteins from urea extract of FTLD-
U brain were resolved on Bis-Tris SDS-PAGE and immunoblotted with anti-C-t-TDP-43 pAb (lane 1) or 
stained with Amido Black (lane 2). N-terminal sequence was done on stained protein bands 
corresponding to the immuno-reactive bands (arrows). Primary sequence of the ~22 kD band was 
identified to be TDP-43 with Arg208 as N-terminus (arrow with *). (B) Schematic representation of TDP-
43 protein highlighting the most prominent features (domains and localization signals) of the full length 
protein, and the four untagged TDP-43 CTFs generated for mammalian cell expression. NLS: nuclear 
localization signal; NES nuclear export signal; RRM: RNA-recognition motif; Gly-rich: glycine-rich 
domain. (C) QBI-293 and N2a cells were transfected with the indicated TDP-43 CTF constructs, and total 
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cell extracts were subsequently analyzed by immunoblotting with C-t TDP-43 pAb. Endogenous TDP-43 
migrates as a 43 kD band in all transfections. 
 
Figure 2. TDP-43 CTFs Expressed in N2a neuroblastoma cells are insoluble and 
hyperphosphorylated. (A) N2a cells 48 hr post-transfection with vector alone or the different TDP-43 
CTFs were sequentially extracted with RIPA (R) and urea buffer (U). Immunoblotting was conducted 
with C-t TDP-43 pAb or p409/410 phospho-specific TDP-43 mAb. Note the slower migrating p409/410 
positive immunobands detected with both antibodies (highlighted with the asterisks) that were only 
recovered in the insoluble fraction of all TDP-43 CTF extracts. GAPDH was used as a loading control. 
(B) Densitometric analysis of C-t TDP-43 pAb immunoblots shown in (A). Immunobands corresponding 
to endogenous TDP-43 (Vector condition) or TDP-43 CTFs were quantified and expressed as percentage 
of RIPA-insoluble/total. Error bars represent S.E.M. of 3 different experiments. One-way ANOVA 
(p=0.0107) shows significant differences between Vector condition and all CTFs (*  p<0.05, Tukey’s 
multiple comparison test). (C) Double-labeling using C-t TDP-43 pAb (green), p409/410 TDP-43 mAb 
(red) and counterstained with DAPI (blue) for nuclei. N2a cells transfected with vector or TDP-43 CTFs 
show that CTF-expressing cells form cytoplasmic aggregates. Phosphorylated TDP-43 was only observed 
in C-t-positive aggregates, but not in endogenous TDP-43 from control or untransfected cells. Scale bar = 
10 μm. (D) Quantification of the percentage of inclusion-bearing cells in TDP-43 CTF-transfected 
Neuro2a cells. Note the correlation between TDP-43 CTF solubility shown in B and aggregate formation. 
Error bars represent S.E.M. (n=3). One-way ANOVA (p=0.0003) followed by Tukey’s multiple 
comparison test. # p<0.05 compared to 177 CTF; ** p<0.01 and *p<0.001 compared to Vector. 
 
Figure 3. Comparison of TDP-43 CTFs from N2a cells and from FTLD-U brains.  
The electrophoretic mobility of a mixture of CTFs TDP-43 from N2a cell lysates (N) was compared with 
sarkosyl-insoluble fraction from FTLD-U cases (F1, F2) before (-) and after (+) dephosphorylation with 
alkaline phosphatase (AP). (A) Immunoblot probed with p409/410 TDP-43 mAb and (B) C-t TDP-43 
pAb. Note that the immunobands from TDP-43 CTFs mixture of the transfected N2a extracts shown in 
(A) (lane N) display similar electrophoretic mobility with CTFs extracted from FTLD-U brain samples 
(F1, F2). The asterisk in (A) denotes the phosphorylated 208 TDP-43 CTF co-migrating with the ~ 22 kD 
band from FTLD-U brains. 
 
Figure 4. Cytoplasmic full length TDP-43 expression results in phosphorylated aggregates. (A) QBI-
293 cells 48 hr post-transfection with empty vector, Myc-TDP-43-WT (WT), or Myc-TDP-43-∆NLS 
(∆NLS) were sequentially extracted with RIPA (R) and urea buffer (U). Immunoblotting was conducted 
with anti-C-t TDP-43 pAb or anti-p409/410 phospho-TDP-43 mAb. Myc-TDP-43 (top band) migrates 
slower than endogenous TDP-43 (lower band). Note that although both WT (nuclear) and ∆NLS 
(cytoplasmic) displayed considerable amounts of RIPA-insoluble material, only the latter was p409/410-
positive. GAPDH was used as a loading control. (B) Double-label immunofluorescence of vector, WT 
and ∆NLS TDP-43 transfected QBI-293 cells immunostained with C-t TDP-43 pAb (green) and p409/410 
TDP-43 mAb (red) antibodies. Only aggregated cytoplasmic TDP-43 is hyperphosphorylated. Scale bar = 
10 μm. 
 
Figure 5. TDP-43 CTFs are ubiquitinated. (A) Double-labeling of N2a cells after transfection with 
vector or TDP-43 CTFs. Cells were stained 48 hr after transfection using anti-C-t TDP-43 pAb (green) 
and anti-Ubiquitin (FK2 mAb, red) antibodies. The majority of TDP-43 aggregates strongly colocalized 
with multi-ubiquitin antibody signal. Scale bar = 10 μm. (B) HA or human-specific TDP-43 mAb 
immunoblots of input or immunoprecipitated N2a cell lysates cotransfected with empty vector or 187 
TDP-43 and HA-tagged ubiquitin (HA-Ub) in the presence (+) or absence (-) of MG132 10 μM (16 hrs). 
Note the presence of the MG132-dependent, ubiquitinated HA positive high-Mr smear (*) when 187 
TDP-43 is expressed (**). Arrows indicate IgG bands.  
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Figure 6. TDP-43 CTF-expression cells display abnormal CFTR mRNA splicing. (A) Representative 
agarose gel electrophoresis analysis of RT-PCR products used to assess CFTR exon 9 inclusion in 
TG13T5-transfected cells. QBI-293 were first transfected with either vector alone, WT TDP-43, a TDP-
43 shRNA or TDP-43 CTFs and 48 hrs later, they were transfected with the TG13T5 CFTR reporter 
plasmid. After another 24 hrs, total RNA was isolated, and RT-PCR was performed using the primers 
indicated in Fig S3B. PCR products were visualized on agarose gels and quantified using the Agilent 
2100 Bioanalyzer. Exon 9 included (+) and excluded (-) RT-PCR products are shown. The arrow 
indicates a previously reported aberrant splicing product (6) generated by a cryptic splicing site. (B) 
Spliced vs unspliced ratios were calculated and then normalized to the values of vector alone transfections. 
Mean values from at least 3 different experiments performed in duplicate are shown with S.E.M. * 
p< 0.05; ** p< 0.01; *** p<0.001 (Student t test vs. vector alone). 
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Figure 1 Igaz et al. 13
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Figure 3 Igaz et al. 15
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on February 23, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
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